Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Australia Suspends 23 Ranitdine Products Contaminated with NDMA

Nov 28 2019

• By Tom Gallen

Vintage looking Withdrawn stamp on a book page

Related Content

FDA Finds Ranitidine Poses Little Risk, But Concerns Linger

Nov 04 2019

Australia Finds ‘Unacceptable’ Levels Of NDMA In 80% of Ranitidine Batches

Oct 30 2019

EMA Tells Firms To Evaluate OTCs For Carcinogenic Nitrosamines

Sep 27 2019

Additional Topics

Australia Asia Pacific Drug Safety Enforcement Drug Review Drug Approval Standards Ingredients Quality Regulation OTC Drugs

More from Compliance

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window